ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

ImmunityBio director Barry J. Simon reported an open-market sale of 23,033 shares of Common Stock at a weighted average price of $7.1769 per share. The sale was executed on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan. After the transaction, he directly holds 2,827,788 shares.

Insights

Insider trading and governance analyst

Routine pre-planned sale; director retains a large remaining stake.

Director Barry J. Simon sold 23,033 shares of ImmunityBio, Inc. Common Stock at a weighted average of $7.1769 per share on June 4, 2026. The transaction is coded as an open-market sale.

A footnote states the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025, which indicates the timing was scheduled in advance rather than opportunistic. Following the sale, he directly owns 2,827,788 shares.

This filing shows a modest net-sell of 23,033 shares relative to his disclosed holdings, suggesting routine portfolio management. Future company filings may provide additional context on any further activity under this trading plan.

Insider Trade Summary 10b5-1

Net Seller: 23,033 shares ($165,306)

Net Sell 1 txn

Insider Simon Barry J.

Role null

Sold 23,033 shs ($165K)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,033	$7.1769	$165K

Holdings After Transaction: Common Stock — 2,827,788 shares (Direct, null)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025. Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 23,033 shares Average sale price: $7.1769 per share Post-transaction holdings: 2,827,788 shares +1 more

4 metrics

Shares sold 23,033 shares Open-market sale on June 4, 2026

Average sale price $7.1769 per share Weighted average price for 23,033 shares

Post-transaction holdings 2,827,788 shares Common Stock held directly after the sale

Sale price range $7.125 to $7.225 per share Range for trades included in the weighted average

Key Terms

Rule 10b5-1 trading plan, weighted average share price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average share price financial

"Represents the weighted average share price of an aggregate total of 23,033 shares sold..."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Barry J.

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		23,033	D	$7.1769(2)	2,827,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

2. Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ImmunityBio (IBRX) director Barry J. Simon report?

Barry J. Simon reported selling 23,033 shares of ImmunityBio Common Stock. The shares were sold in the open market at a weighted average price of $7.1769 per share, as disclosed in his Form 4 insider trading report.

At what price did Barry J. Simon sell ImmunityBio (IBRX) shares?

He sold 23,033 ImmunityBio shares at a weighted average price of $7.1769. The footnotes note a sale price range between $7.125 and $7.225 per share, with details available upon request from the issuer or regulators.

When did the reported ImmunityBio (IBRX) insider sale by Barry J. Simon occur?

The reported sale occurred on June 4, 2026. On that date, Barry J. Simon executed an open-market sale of 23,033 shares of ImmunityBio Common Stock under a pre-arranged Rule 10b5-1 trading plan.

How many ImmunityBio (IBRX) shares does Barry J. Simon own after the sale?

After the sale, Barry J. Simon directly owns 2,827,788 shares of ImmunityBio Common Stock. This post-transaction holding is disclosed in the Form 4 as the total number of shares he holds following the reported sale.

Was Barry J. Simon’s ImmunityBio (IBRX) share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted on December 18, 2025. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than decided at the moment.

What price range applied to Barry J. Simon’s ImmunityBio (IBRX) share sale?

The 23,033 shares were sold within a price range of $7.125 to $7.225 per share. The reported $7.1769 figure is a weighted average price, and detailed breakdowns by individual trade price are available upon request from specified parties.